Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
November 14, 2023Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …
Enhanc3D Genomics appoints Hazel Jones as chief operating officer
November 14, 2023Business Services Enhanc3D Genomics, Hazel Jones, chief operating officer
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer. This appointment marks part of the company’s …
Anthony Johnson appointed NanoSyrinx’s non-executive director
November 14, 2023Business Services Anthony Johnson, NanoSyrinx, non-executive director
NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director. This appointment marks part of …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark
November 10, 2023Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …
Eli Lilly’s Zepbound approved by FDA for chronic weight management
November 9, 2023Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
J&J’s to submit surgical robot to FDA in 2024
November 8, 2023Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot
Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …
Bit.bio announces cell therapy pipeline
November 8, 2023Medical Communications Hepatology, bit.bio, cell therapy, liver failure
Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter …
Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment
November 7, 2023Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration
Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …
Evotec and Dewpoint Therapeutics enter strategic partnership
November 7, 2023Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate …
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …
AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment
November 6, 2023Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria
AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …
Angiex’s IND application for AGX101 cleared by FDA
November 3, 2023Medical Communications AGX101, Angiex, FDA, Oncology
Angiex has announced that the US Food and Drug Administration has cleared its Investigational New Drug (IND) application for AGX101, …
FDA approves Phathom Pharmaceuticals’ Voquezna for erosive GERD
November 3, 2023Medical Communications Erosive GERD, FDA, Gastrointestinal tract, Phathom Pharmaceuticals, Voquezna
Phathom Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) tablets 10mg and 20mg, …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap
November 2, 2023Business Services AbbVie, Aldeyra Therapeutics, Opthalmology, reproxalap
Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement for the license to develop, …
ViroCell and GOSH gain MHRA manufacturing approval
November 1, 2023Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors
ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
